Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global
healthcare company, and Noom, a leading behaviour change company,
today announced a collaboration on digital health solutions focusing
on weight management and education, with the aim of improving the
lives of people living with obesity. The collaboration follows a
successful 8-month pilot that combined Noom's proven, science-backed
behaviour change programmes with Novo Nordisk's more than 95 years of
experience in helping people living with chronic diseases. This
collaboration, as one of many ways Novo Nordisk is partnering to
improve care, will make solutions for behaviour change and education
available to people with obesity in the US.

"We are passionate about improving the lives of people with
obesity and finding new solutions to support respectful and complete
care, which includes lifestyle change and medical management," said
Camilla Sylvest, Novo Nordisk executive vice president, Commercial
Strategy & Corporate Affairs. "We believe that the combination of
Noom's services, with Novo Nordisk's offerings to support people with
obesity, will help educate and empower people with obesity to lose
weight, keep it off - and live healthy lives."

Noom's solutions seek to understand individual motivations and
obstacles and use cutting-edge technology, including artificial
intelligence, behavioural coaching by over 1,000 personal health
coaches, data and wellness insights, to guide people towards
sustainable change.

"Sustainable change can't happen in a vacuum, and those living
with obesity who want to manage their weight are in need of
personalised human coaching to help them change their habits, so they
can lose weight for good," said Saeju Jeong, CEO and co-founder of
Noom. "We've worked with the Novo Nordisk team for over a year and
have engaged with over 4,000 people with obesity. We're enthused by
the exciting feedback and know that by jointly testing and refining
what works, we will continue to deliver much-needed, sustainable
solutions and support, as part of a scientific, insight-driven
treatment plan."

About obesity

Obesity is a complex, chronic disease that is influenced by
multiple aspects, including physiological, psychological, genetic,
environmental and socioeconomic factors.1 It is associated with many
serious health consequences2 and decreased life expectancy.3 Obesity
is not a life choice or simply a question about willpower4 and
necessary help and support can be hard to find. There are few
healthcare professionals trained in obesity care and patients often
see their excess weight as something they should be able to solve on
their own.5,6 Like any other chronic disease, the long-term
management of obesity requires a full spectrum of treatment
approaches, including lifestyle change and intervention, as well as
pharmacotherapy or surgery.7 The global increase in the prevalence of
obesity is a public health issue that has severe cost implications to
healthcare systems.8,9 In 2016, 13% of adults, or approximately 650
million adults, were living with obesity worldwide.8

About Noom, Inc.

Noom is the world's leading behaviour change company, disrupting
the weight loss and healthcare industries. By combining the power of
artificial intelligence, mobile tech, and psychology with the empathy
of over 1,000 personal coaches, Noom helps people live healthier
lives by changing their long-term habits. More than 50 million people
have benefited from Noom's behaviour change courses, including its
virtual diabetes prevention programme, which was the first of its
kind to be recognised by the CDC. The Noom platform is already being
used by leading healthcare and pharmaceutical companies to improve
treatment outcomes for patients worldwide. The company is
headquartered in New York City with offices in Seoul and Tokyo.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 41,600 people in 80 countries and markets its
products in more than 170 countries. For more information, visit
novonordisk.com (file:///Users/nip/Desktop/Corporate%20Communications
/novonordisk.com), Facebook (http://www.facebook.com/novonordisk),
Twitter (http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.youtube.com/novonordisk).

Changing Obesity(TM) is our long-term commitment to improve the
lives of people with obesity by changing how the world sees, prevents
and treats obesity.

Further information

Media, Noom: NA press@noom.com
Media, Novo Nordisk:
Kristine Kruse Zeij +45 3075 1987 kstk@novonordisk.com
Investors, Novo Nordisk:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

References

1. National Institutes of Health. Clinical Guidelines On The
Identification, Evaluation, And Treatment Of Overweight And
Obesity In Adults. Available at:
http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Last
accessed: April 2018.
2. Guh DP, Zhang W, Bansback N, et al. The incidence of
co-morbidities related to obesity and overweight: a systematic
review and meta-analysis. BMC Public Health. 2009; 9:1-20.
3. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and
cause-specific mortality in 900 000 adults: collaborative analyses
of 57 prospective studies. Lancet. 2009; 373:1083-1096.
4. Rosen H. Is Obesity A Disease or A Behavior Abnormality? Did the
AMA Get It Right? . Mo Med. 2014; 111:104-108.
5. Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to
Effective Obesity Care: Results from the National ACTION Study.
Obesity. 2018; 26:61-69.
6. Caterson I, Alfadda A, Auerbach P, et al. Gaps to bridge:
misalignment between perception, reality, and action in obesity.
Diabetes Obes Metab. 2019:1-11.
7. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline
for the management of overweight and obesity in adults: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines and The Obesity Society.
Circulation. 2014; 129:S102-138.
8. World Health Organization. Obesity and Overweight Factsheet no.
311. Available at:
http://www.who.int/mediacentre/factsheets/fs311/en/. Last
accessed: September 2019.
9. Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical
Expenditures Associated with Reductions in Body Mass Index Among
US Adults with Obesity, by Diabetes Status. Pharmacoeconomics.
2015; 33:707-722.

Logo - https://mma.prnewswire.com/media/1004450/Novo_Nordisk_and_N
oom_Logo.jpg

Photo - https://mma.prnewswire.com/media/1004258/Saeju_Jeong_Camil
la_Sylvest.jpg

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell